Zinc oxide thin-film transistors fabricated at low temperature by chemical spray pyrolysis

We report the electrical behavior of undoped zinc oxide thin-film transistors (TFTs) fabricated by low-temperature chemical spray pyrolysis. An aerosol system utilizing aerodynamic focusing was used to deposit the ZnO. Polycrystalline films were subsequently formed by annealing at the relatively low temperature of 140°C. The saturation mobility of the TFTs was 2 cm2/Vs, which is the highest reported for undoped ZnO TFTs manufactured below 150°C. The devices also had an on/off ratio of 104 and a threshold voltage of −3.5 V. These values were found to depend reversibly on measurement conditions

Effects of hydrogen plasma treatment on the electrical behavior of solution-processed ZnO transistors

The effects of hydrogen plasma treatment on the active layer of top-contact zinc oxide thin film transistors are reported. The transfer characteristics of the reference devices exhibited large hysteresis effects and an increasing positive threshold voltage (VTH) shift on repeated measurements. In contrast, following the plasma processing, the corresponding characteristics of the transistors exhibited negligible hysteresis and a very small VTH shift; the devices also possessed higher field effect carrier mobility values. These results were attributed to the presence of functional groups in the vicinity of the semiconductor/gate insulator interface, which prevents the formation of an effective channel

The project of a high-power FEL driven by an SC ERL at KAERI

The project of a high-power FEL at Korea Atomic Energy Research Institute and its recent status are described. The FEL is driven by a superconducting energy recovery linac. The first-stage machine will operate in the far IR region and its CW power is expected to be a few kW. Possible upgrade of the machine is also considered. The upgraded machine will operate in the near IR region and its expected power is a few tens kW.Описан проект мощного ЛСЭ в Корейском институте атомной энергии, а также текущее состояние дел. В ЛСЭ будет использован сверхпроводящий линак-рекуператор. Машина первой очереди будет работать в дальнем ИК-диапазоне, ее ожидаемая средняя мощность несколько киловатт. Рассматривается возможная модернизация машины. Модернизированная машина будет генерировать десятки киловатт средней мощности в ближнем ИК-диапазоне.Описано проект потужного ЛВЕ в Корейському інституті атомної енергії, а також поточний стан справ. У ЛВЕ буде використаний надпровідний лінак-рекуператор. Машина першої черги буде працювати в далекому ІЧ-діапазоні, її очікувана середня потужність − кілька кіловат. Розглядається можлива модернізація машини. Модернізована машина буде генерувати десятки кіловатів середньої потужності в ближньому ІЧ-діапазоні

The project of a high-power FEL driven by an SC ERL at KAERI

The project of a high-power FEL at Korea Atomic Energy Research Institute and its recent status are described. The FEL is driven by a superconducting energy recovery linac. The first-stage machine will operate in the far IR region and its CW power is expected to be a few kW. Possible upgrade of the machine is also considered. The upgraded machine will operate in the near IR region and its expected power is a few tens kW.Описан проект мощного ЛСЭ в Корейском институте атомной энергии, а также текущее состояние дел. В ЛСЭ будет использован сверхпроводящий линак-рекуператор. Машина первой очереди будет работать в дальнем ИК-диапазоне, ее ожидаемая средняя мощность несколько киловатт. Рассматривается возможная модернизация машины. Модернизированная машина будет генерировать десятки киловатт средней мощности в ближнем ИК-диапазоне.Описано проект потужного ЛВЕ в Корейському інституті атомної енергії, а також поточний стан справ. У ЛВЕ буде використаний надпровідний лінак-рекуператор. Машина першої черги буде працювати в далекому ІЧ-діапазоні, її очікувана середня потужність − кілька кіловат. Розглядається можлива модернізація машини. Модернізована машина буде генерувати десятки кіловатів середньої потужності в ближньому ІЧ-діапазоні

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: Prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial

Aims Statins reduce cardiovascular risk in patients with acute coronary syndrome (ACS) and normal-to-moderately impaired renal function. It is not known whether proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors provide similar benefit across a range of renal function. We determined whether effects of the PCSK9 inhibitor alirocumab to reduce cardiovascular events and death after ACS are influenced by renal function. ................................................................................................................................................................................................... Methods ODYSSEY OUTCOMES compared alirocumab with placebo in patients with recent ACS and dyslipidaemia despite and results intensive statin treatment. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m was exclusionary. In 18 918 patients, baseline eGFR was 82.8 ± 17.6 mL/min/1.73 m , and low-density lipoprotein cholesterol (LDL-C) was 92 ± 31 mg/dL. At 36 months, alirocumab decreased LDL-C by 48.5% vs. placebo but did not affect eGFR (P = 0.65). Overall, alirocumab reduced risk of the primary outcome (coronary heart disease death, non-fatal myocardial infarction, ischaemic stroke, or unstable angina requiring hospitalization) with fewer deaths. There was no interaction between continuous eGFR and treatment on the primary outcome or death (P = 0.14 and 0.59, respectively). Alirocumab reduced primary outcomes in patients with eGFR >_90 mL/min/1.73 m (n = 7470; hazard ratio 0.784, 95% confidence interval 0.670–0.919; P = 0.003) and 60 to <90 (n = 9326; 0.833, 0.731–0.949; P = 0.006), but not in those with eGFR < 60 (n = 2122; 0.974, 0.805–1.178; P = 0.784). Adverse events other than local injection-site reactions were similar in both groups across all categories of eGFR. ................................................................................................................................................................................................... Conclusions In patients with recent ACS, alirocumab was associated with fewer cardiovascular events and deaths across the range of renal function studied, with larger relative risk reductions in those with eGFR > 60 mL/min/1.73 m 2 2 2 2The trial was funded by Sanofi and Regeneron Pharmaceuticals, Inc

Quasiparticle dynamics in ferromagnetic compounds of the Co-Fe and Ni-Fe systems

We report a theoretical study of the quasiparticle lifetime and the quasiparticle mean free path caused by inelastic electron-electron scattering in ferromagnetic compounds of the Co-Fe and Ni-Fe systems. The study is based on spin-polarized calculations, which are performed within the $GW$ approximation for equiatomic and Co- and Ni-rich compounds, as well as for their constituents. We mainly focus on the spin asymmetry of the quasiparticle properties, which leads to the spin-filtering effect experimentally observed in spin-dependent transport of hot electrons and holes in the systems under study. By comparing with available experimental data on the attenuation length, we estimate the contribution of the inelastic mean free path to the latter.Comment: 10 pages, 10 figure

Peripheral artery disease and venous thromboembolic events after acute coronary syndrome role of lipoprotein(a) and modification aby alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background:Patients with acute coronary syndrome are at risk for peripheral artery disease (PAD) events and venous thromboembolism (VTE). PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C) levels. Our objective was to ascertain whether PCSK9 inhibition reduces the risk of PAD events or VTE after acute coronary syndrome, and if such effects are related to levels of lipoprotein(a) or LDL-C.Methods:This was a prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome), which was conducted in 18 924 patients with recent acute coronary syndrome on intensive or maximum-tolerated statin treatment who were randomized to the PCSK9 inhibitor alirocumab or placebo. In a prespecified analysis, PAD events (critical limb ischemia, limb revascularization, or amputation for ischemia) and VTE (deep vein thrombosis or pulmonary embolism) were assessed. LDL-C was corrected (LDL-C-corrected) for cholesterol content in lipoprotein(a).Results:At baseline, median lipoprotein(a) and LDL-C-corrected were 21 and 75 mg/dL, respectively; with alirocumab, median relative reductions were 23.5% and 70.6%, respectively. PAD events and VTE occurred in 246 and 92 patients, respectively. In the placebo group, risk of PAD events was related to baseline quartile of lipoprotein(a) (P-trend=0.0021), and tended to associate with baseline quartile of LDL-C-corrected (P-trend=0.06); VTE tended to associate with baseline quartile of lipoprotein(a) (P-trend=0.06), but not LDL-C-corrected (P-trend=0.85). Alirocumab reduced risk of PAD events (hazard ratio [HR], 0.69 [95% CI, 0.54-0.89]; P=0.004), with nonsignificantly fewer VTE events (HR, 0.67 [95% CI, 0.44-1.01]; P=0.06). Reduction in PAD events with alirocumab was associated with baseline quartile of lipoprotein(a) (P-trend=0.03), but not LDL-C-corrected (P-trend=0.50). With alirocumab, the change from baseline to Month 4 in lipoprotein(a), but not LDL-C-corrected, was associated with the risk of VTE and the composite of VTE and PAD events.Conclusions:In statin-treated patients with recent acute coronary syndrome, risk of PAD events is related to lipoprotein(a) level and is reduced by alirocumab, particularly among those with high lipoprotein(a). Further study is required to confirm whether risk of VTE is related to lipoprotein(a) level and its reduction with alirocumab.Registration:URL: ; Unique identifier: NCT01663402.Cardiolog

Clinical efficacy and safety of alirocumab after acute coronary syndrome according to achieved level of low-density lipoprotein cholesterol a propensity score-matched analysis of the ODYSSEY OUTCOMES trial

BACKGROUND: Recent international guidelines have lowered recommended target levels of low-density lipoprotein cholesterol (LDL-C) for patients at very high risk for major adverse cardiovascular events (MACE). However, uncertainty persists whether additional benefit results from achieved LDL-C levels below the conventional targets. Inferences from previous analyses are limited because patients who achieve lower versus higher LDL-C on lipid-lowering therapy differ in other characteristics prognostic for MACE and because few achieved very low LDL-C levels. To overcome these limitations, we performed a propensity score-matching analysis of the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) which compared alirocumab with placebo in 18 924 patients with recent acute coronary syndrome receiving intensive or maximum-tolerated statin treatment.METHODS: Patients on alirocumab were classified in prespecified strata of LDL-C achieved at 4 months of treatment: 50 mg/dL (n=2197). For each stratum, MACE (coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or hospitalization for unstable angina) after month 4 was compared in patients receiving placebo with similar baseline characteristics and adherence by using 1:1 propensity score matching.RESULTS: Across achieved LDL-C strata of the alirocumab group, patients differed by baseline LDL-C, lipoprotein(a), use of intensive statin therapy, study medication adherence, and other demographic, medical history, biometric, and laboratory criteria. After propensity score matching, characteristics were similar in corresponding patients of the alirocumab and placebo groups. Treatment hazard ratio, 95% CI, and absolute risk reduction (number per 100 patient-years) for MACE were similar in those with achieved LDL-C 50 mg/dL had poorer adherence and derived less benefit (hazard ratio, 0.87 [95% CI, 0.73-1.04]; absolute risk reduction, 0.62). No safety concerns were associated with a limited period of LDL-C levels <15 mg/dL.CONCLUSIONS: After accounting for differences in baseline characteristics and adherence, patients treated with alirocumab who achieved LDL-C levels <25 mg/dL had a reduction in the risk of MACE that was similar to that of patients who achieved LDL-C levels of 25 to 50 mg/dL.Cardiolog

Standalone vertex finding in the ATLAS muon spectrometer

A dedicated reconstruction algorithm to find decay vertices in the ATLAS muon spectrometer is presented. The algorithm searches the region just upstream of or inside the muon spectrometer volume for multi-particle vertices that originate from the decay of particles with long decay paths. The performance of the algorithm is evaluated using both a sample of simulated Higgs boson events, in which the Higgs boson decays to long-lived neutral particles that in turn decay to bbar b final states, and pp collision data at √s = 7 TeV collected with the ATLAS detector at the LHC during 2011

Measurements of Higgs boson production and couplings in diboson final states with the ATLAS detector at the LHC

Measurements are presented of production properties and couplings of the recently discovered Higgs boson using the decays into boson pairs, H →γ γ, H → Z Z∗ →4l and H →W W∗ →lνlν. The results are based on the complete pp collision data sample recorded by the ATLAS experiment at the CERN Large Hadron Collider at centre-of-mass energies of √s = 7 TeV and √s = 8 TeV, corresponding to an integrated luminosity of about 25 fb−1. Evidence for Higgs boson production through vector-boson fusion is reported. Results of combined fits probing Higgs boson couplings to fermions and bosons, as well as anomalous contributions to loop-induced production and decay modes, are presented. All measurements are consistent with expectations for the Standard Model Higgs boson